OncologyOnline.net

Oncology Xagena

Ten years ago, the Adenoma Prevention With Celecoxib ( APC ) trial showed that the selective cyclooxygenase-2 ( COX-2 ) inhibitor reduced the incidence of post-polypectomy adenoma by 38% and advanced ...


Long-term, regular Aspirin ( Acetylsalicylic acid ) use was associated with reduced risk of death from several different kinds of cancers. Accumulating evidence suggests that Aspirin not only reduc ...


In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins say they have found no evidence of cytomegalovirus ( CMV ) infection and con ...


Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the gut ( the microbiome ) and response to immunotherapy. In the study, the ability o ...


Indoleamine 2,3-dioxygenase-1 ( IDO1 ) catalyzes the degradation of tryptophan to N-formyl-kynurenine. Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveilla ...


With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a study published in The American Journal of Pathology, resea ...


New patient-reported quality-of-life data from an exploratory endpoint in the pivotal phase 3 CheckMate -141 trial evaluating Nivolumab ( Opdivo ) in patients with recurrent or metastatic squamous cel ...


A treatment harnesses the immune system to shrink tumors in bladder cancer patients that cannot take the most effective chemotherapy. These are the findings of a clinical trial led by researchers at ...


Results from phase 2 CABOSUN trial of Cabozantinib ( Cabometyx ) versus Sunitinib ( Sutent ) in previously untreated advanced renal cell carcinoma were presented at the European Society for Medical On ...


Nivolumab ( Opdivo ) maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Cong ...


Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening or death ( progression free survival, PFS ) by 66% compared to Crizotinib ( Xalk ...


A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with Panitumumab plus Vemurafenib. Pre-existing cells with increased MET gene copy ...


The results for Nivolumab ( Opdivo ) in the cohort of patients with metastatic urothelial cancer ( n=78 ), the most common type of bladder cancer, after Platinum-based therapy from CheckMate -032, a p ...


Interim data from the phase 2 CheckMate -142 trial evaluating Nivolumab ( Opdivo ) alone or in combination with Ipilimumab ( Yervoy ) in patients with previously treated metastatic colorectal cancer, ...


The prognostic value of BRAF and KRAS mutations in patients who have undergone resection for colon cancer and have been treated with combination Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX)-base ...